NEW YORK, Dec. 5, 2011 /PRNewswire/ -- TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, today announced the relocation of its corporate headquarters to New Jersey.
The new facility located at 4400 Route 9 South in Manalapan, New Jersey will accommodate the Company's current staff and enable further expansion for the Company's future growth.
Kelly Hickel, CEO of TheraBiogen, commented, "As the demand for our products continues to grow, we have decided to relocate our corporate offices to New Jersey where we will have the capacity to expand with lower operating costs and more flexibility." He added, "It is an added benefit to be located in New Jersey, the heart of America's pharmaceutical and over the counter drug industry."
Thera Max™ is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts, Big Y Supermarkets and others. For more information on Thera Max™ visit our website at www.theramaxrelief.com, our Facebook page at facebook.com/theramaxnasalspray or follow us on Twitter at http://twitter.com/TheraMaxRelief.
About TheraBiogen, Inc.TheraBiogen is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.Company Contact: Public Relations Contact: Investor Contact:TheraBiogen, Inc.
Boutcher & BoutcherKelly T. Hickel, CEO
Megale Public Relations
|SOURCE TheraBiogen, Inc.|
Copyright©2010 PR Newswire.
All rights reserved